GEN Article: The Greening of Biopharma

The Greening of Biopharma: From operational overhauls to product design, biomanufacturing and bioprocessing companies reduce their environmental impact

The biopharmaceutical industry aims to reduce their greenhouse-gas emissions and environmental impact as many companies commit to achieving net-zero by 2050.  For many biopharma firms, reducing environmental footprint is no longer optional: customers and partners increasingly demand strong ESG (Environmental, Social, Governance) performance.  The push for sustainability in the industry is broad, involving many parts of the supply chain, from chemical processes and manufacturing operations, to product design, packaging, and supplier management.

The article mentions that VERDOT has been monitoring its carbon footprint for 15 years, noting that its 1 and 2 emissions (i.e., direct and energy-related emissions) are already low compared to the rest of the industry.